Practice Guideline Briefs

CDC Studies the Effectiveness of PCV7 Immunization in Children

Am Fam Physician. 2006 Mar 15;73(6):1111.

The 7-valent pneumococcal conjugate vaccine (PCV7) was approved in 2000 to prevent pneumococcal disease in children younger than five years. The Centers for Disease Control and Prevention (CDC) has released results from a study evaluating the vaccine’s impact on invasive pneumococcal disease in children since its approval. The report, “Direct and Indirect Effects of Routine Vaccination of Children with 7-Valent Pneumococcal Conjugate Vaccine on Incidence of Invasive Pneumococcal Disease—United States, 1998–2003,” was published in the September 16, 2005, issue of Morbidity and Mortality Weekly Report and is available online at http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5436a1.htm.

The population-based study showed that the vaccine effectively prevented invasive pneumococcal disease in the targeted age group as well as in older children and adults; more than twice as many cases were prevented through indirect effects on the disease than through the direct protective effects of the vaccine. Increases in disease caused by serotypes not included in the vaccine were small compared with the overall decrease in vaccine-serotype disease. Ongoing surveillance is needed to confirm the effectiveness of PCV7.


Copyright © 2006 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact afpserv@aafp.org for copyright questions and/or permission requests.

Want to use this article elsewhere? Get Permissions


Article Tools

  • Print page
  • Share this page
  • AFP CME Quiz

Information From Industry

Navigate this Article